EE?ANUeEEE IAOEIAI-AeINE?AeIEE ?INOEOOO

AAIAOIEIA?? OA IA?AEEAAIIss E?IA?

IIC OE?A?IE

EA?IEUe TH??e Noaiaiiae/

OAeE 616-006.441+616.155.392.2]:612.017.01-085/-089

AIEEA E?EOAAIIss IA OAIIOEI?*IO OA?AEOA?ENOEEO E?IOI?AeIEO EE?OEI OAI?EO
IA O?II?*I? E?IOII?IE?OA?AOEAI? CAOAI?THAAIIss C ?IOIIEIE OeEOIIAI?ssIE

14.01.31 — aaiaoieia?y oa o?ainooc?ieia?y

Aaoi?aoa?ao

aeena?oaoe?? ia caeiaoooy iaoeiaiai nooiaiy

eaiaeeaeaoa iaaee/ieo iaoe

Ee?a — 1998

1

Aeena?oaoe??th ? ?oeiien.

?iaioa aeeiiaia o Euea?anueeiio o?e?ae? Ee?anueeiai iaoeiai-aeine?aeiiai
?inoeoooo aaiaoieia?? oa ia?aeeaaiiy e?ia? IIC Oe?a?ie.

Iaoeia? ea??aieee — aeieoi? iaaee/ieo iaoe, i?ioani?

AEAIANUeEA ss?ineaaa ?ee?aia,

caa?aeoaa/ a?aeae?eaiiy aaiaoieia?? Euea?anueeiai o?e?aeo

Ee?anueeiai iaoeiai-aeine?aeiiai ?inoeoooo aaiaoieia??

oa ia?aeeaaiiy e?ia?

— aeieoi? iaaee/ieo iaoe, i?ioani?

EIA?INUeEEE Aieiaeeie? Inoaiiae/,

caa?aeoaa/ eaai?aoi??? ?ioiieia?? Euea?anueeiai o?e?aeo

Ee?anueeiai iaoeiai-aeine?aeiiai ?inoeoooo aaiaoieia??

oa ia?aeeaaiiy e?ia?

Io?oe?ei? iiiiaioe — aeieoi? iaaee/ieo iaoe, i?ioani?

AAEAeOEIAA Na?oeaia Ieoaee?aia,

caa?aeoaa/ eaoaae?e aaiaoieia?? Ee?anueei? iaaee/ii? aeaaeai??

i?neyaeeieiiii? ina?oe IIC Oe?a?ie

— aeieoi? iaaee/ieo iaoe, i?ioani?

CA??EIAA Aeea Naiai?aia,

i?ia?aeiee iaoeiaee ni?a?ia?oiee eaai?aoi??? oeeoieia??

oa ?ioiieia?? Ee?anueeiai IAe? aaiaoieia?? oa ia?aeeaaiiy e?ia?

I?ia?aeia onoaiiaa — ?inoeooo aenia?eiaioaeueii? iaoieia??,
iieieia?? oa ?aae?ia?ieia?? ?i. ?.?. Eaaaoeueeiai IAI Oe?a?ie,

a?aeae?e ?ioiioeeoio?i??, i. Ee?a

Caoeno aeena?oaoe?? a?aeaoaeaoueny «…11..» .eenoiiaaea. 1998 ?. i
.14:30… aiaeei? ia can?aeaii? niaoe?ae?ciaaii? a/aii? ?aaee Ae
26.612.01 a Ee?anueeiio IAe? aaiaoieia?? oa ia?aeeaaiiy e?ia? (254060,
i.Ee?a, aoe.I.Aa?e?inueeiai, 12).

C aeena?oaoe??th iiaeia iciaeiieoenue o a?ae?ioaoe? Ee?anueeiai IAe?
aaiaoieia?? oa ia?aeeaaiiy e?ia?.

Aaoi?aoa?ao ?ic?neaiee «..01..» ..aeiaoiy 1998 ?.

A/aiee nae?aoa?

niaoe?ae?ciaaii? a/aii? ?aaee EII?NA?AIEI A.A.

AEOOAEUeI?NOUe OAIE

O?ii?/iei e?ioii?ie?oa?aoeaiei caoai?thaaiiyi (OEIC) i?eoaiaiiee
?icaeoie oneeaaeiaiue ?ioiiiai aaiaco. Ca?aeii c aeaieie ??cieo aaoi??a,
?ioii? oeeoiiai?? oneeaaeiththoue ia?aa?a OEIC o 5-25% iaoe??io?a
(Z.M.Sthoeger ? ni?aaao., 1993; K.Gronbek ? ni?aaao., 1996). Iae/ano?oa
oea ?ioiia aaiie?oe/ia aiai?y (?AA) oa ?ioiia o?iiaioeeoiiai?/ia io?io?a
(?OI).

Iacaaaeath/e ia oa, ui aeieeiaiiy aiai?? /e o?iiaioeeoiiai?? ? iniiaith
aeey ae?aaiinooaaiiy i?ci?o noaae?e (III, IV ca Rai) o?ii?/ii?
e?ioi?aeii? eaeeai?? (OEE), i?iaiic caoai?thaaiiy a?aeiinii o?eaaeino?
aeeooy naia i?e ?ioiieo oeeoiiai?yo ? cia/ii ni?eyoeea?oei, i?ae i?e
oeeoiiai?yo iaoaieanoe/iiai aaiaco (ss.E.Auaianeay ? ni?aaao., 1996;
A.Haubenstock, R.Zalucky, 1985; G.Majumdar ? ni?aaao., 1993). Ie??i
oiai, e?eoaaeueia oaeoeea i?e aeieeiaii? ?ioiieo oeeoiiai?e
a?ae??ciy?oueny a?ae o?aaeeoe?eii? oa?ai?? OEE ? caeeoa?oueny aeaeaeith
a?ae ae??oaiiy, ia aeeaey/enue ia cia/iee a?naiae e?eoaaeueieo cania?a
(ei?oeeinoa?i?aei? ai?iiie, aee?eoth/? i?aia?aoe, eaeeaieaciaoa?ac,
nieaiaeoii?y oa ?io?).

Aeine?aeaeaiiy inoaii?o ?ie?a iieacaee, ui iaoai?cie ae??
o?i?ioa?aiaaoe/ieo cania?a oa a?ieia?/ii aeoeaieo ?a/iaei, ui
canoiniaothoueny a e?eoaaii? ceiye?nieo caoai?thaaiue, neeaaei? ? aei
e?ioey ia aeyniai? (J.E.Wertz, M.R.Haenley, 1996). A?aeiii, ui an?
e?eoaaeuei? caniae caioneathoue caaaeuei? iaoai?cie aiiioico, ye?
?aaoeththoueny ?yaeii iieiaai?a (J.L.Binet ? ni?aaao., 1996; I.Korner ?
ni?aaao., 1997). Nooi?iue aiiioico A-ee?oei i?e OEE ? aeici- ?
/anicaeaaeiei. Aieea e?eoaaeueieo i?aia?ao?a ia ceiye?ni? ? e?ioi?aei?
ee?oeie caeaaeeoue a?ae yaeu aeoeaaoe?? /e ?ai?an?? a aaiii?, ye? ia
iiaeooue ia noi?iaiaeaeoaaoenue ci?iaie oaiioeio ee?oeie. Naia oiio
aea/aiiy ci?i oaiioei?/ii? oa?aeoa?enoeee iaia?aie ceiye?nieo ee?oei o
oai?eo ia A-OEE c ?ioiieie oneeaaeiaiiyie a i?ioean? e?eoaaiiy c
o?aooaaiiyi eiai aoaeoeaiino? ? ia?niaeoeaiei a ieai? aeai?o ?
iaa?oiooaaiiy iaea?eueo ?aoe?iiaeueieo i?ia?ai oa?ai??, ui aeicaieeoue
oaeineiiaeeoe e?eoaaeueio oaeoeeo i?e oe?e iaoieia??.

CA’ssCIE ?IAIOE C IAOEIAEIE I?IA?AIAIE, IEAIAIE, OAIAIE

Ia?aiee iai?yiie aeine?aeaeaiiy aaciina?aaeiuei iia’ycaiee c
iaoeiai-aeine?aeieie ?iaioaie Euea?anueeiai o?e?aeo Ee?anueeiai IAe?AIE
(?? Aea?ae?a?no?aoe?? 0194U022112 oa UA 01012649?).

IAOA AeINE?AeAEAIIss

Aaeineiiaeaiiy e?eoaaeueii? oaeoeee o oai?eo o?ii?/ieie
e?ioii?ie?oa?aoeaieie caoai?thaaiiyie c ?ioiieie oneeaaeiaiiyie ia
iniia? aeyniaiiy ci?i oaiioei?/ii? oa?aeoa?enoeee e?ioi?aeieo ee?oei
ia?eoa?e/ii? e?ia? a i?ioean? ??cieo noai oa?ai?? c a?aooaaiiyi ??
aoaeoeaiino?.

CAAeA*? AeINE?AeAEAIIss

1. Aeynieoe iniaeeaino? ?ioiieia?/iiai oaiioeio e?ioi?aeieo ee?oei
ia?eoa?e/ii? e?ia? oai?eo ia A-OEIC c ?ioiieie oneeaaeiaiiyie.

2. Aea/eoe ci?ie ?ioiioaiioei?/ii? oa?aeoa?enoeee eaeeai?/ieo A-ee?oei
oa nenoaie O-e?ioioeeo?a ia?eoa?e/ii? e?ia? oai?eo ia A-OEE c ?ioiieie
oneeaaeiaiiyie i?ae ae??th ??cieo noai e?eoaaiiy.

3. Aeynieoe aeni?an?th A-, O- oa aeoeaaoe?eieo aioeaai?a ia e?ioioeeoao
ia?eoa?e/ii? e?ia? i?ney nieaiaeoii?? o oai?eo ia iaaiaeaee?inueeo
e?ioiio (A-IAE) c ?ioiieie oneeaaeiaiiyie oa aac oneeaaeiaiue.

4. O oai?eo ia A-OEE c ?ioiieie oneeaaeiaiiyie ni?anoaaeoe /anoioo ?
o?eaae?noue ?ai?n?? i?ney ??cieo iaoiae?a e?eoaaiiy c? ci?iaie
?ioiioaiioei?/ii? oa?aeoa?enoeee e?ioioeeo?a ia?eoa?e/ii? e?ia? ? ia
oe?e iniia? iaa?oiooaaoe oa aaeineiiaeeoe e?eoaaeueio oaeoeeo.

IAOEIAA IIAECIA IAeA?AEAIEO ?ACOEUeOAO?A

Aia?oa aeyaeai? a?aei?iiino? ?ioiioaiioei?/ii? oa?aeoa?enoeee
e?ioioeeo?a ia?eoa?e/ii? e?ia? oai?eo ia OEE c ?ioiieie oneeaaeiaiiyie
i?ae aieeaii ??cieo noai oa?ai??. Iieacaii, ui aiane?aeie e?eoaaiiy
a?aeaoaathoueny e?euee?ni? ? ye?ni? ci?ie oaiioei?/ii? oa?aeoa?enoeee
eaeeai?/ieo A-ee?oei. E?euee?ni? ci?ie i?iyaeythoueny cieaeaiiyi ??aiy
aeni?an?? A-ee?oeiieo ia?ea??a, a ?o ae?aaeai?noue ei?aeth? c
aoaeoeai?noth oa?ai??. sse?ni? ci?ie — oea c?inoaiiy aeni?an??
aeoeaaoe?eieo aioeaai?a; iae/ano?oa ca?eueoo?oueny aeni?an?y CD25R,
?aoeaioi?a IL-2. Aia?oa iieacaii, ui aaaeeeaei oaeoi?ii aoaeoeaiino?
oa?ai?? i?e OEE ? i?aeaeuaiiy ??aiy aeni?an?? ia eaeeai?/ieo ee?oeiao
Fas-?aoeaioi?a (CD95), e?aoaaiiy yeiai oaeoi?ii iae?ico iooeei caionea?
i?ia?aio aiiioico. Aeyaeaii, ui c?inoaiiy e?eueeino? CD95+-ee?oei ianoa?
i?ney i?ia?ai e?eoaaiiy, ui a?aecia/athoueny nooo?aith aoaeoeai?noth,
oiaoi i?ney eo?no oa?ai?? a?ie?enoeiii c i?aaei?cieiiii oa i?ney noaie
NI? o oai?eo ia OEE c ?ioiieie oneeaaeiaiiyie ?, iniaeeai, i?ney
nieaiaeoii?? o oai?eo ia OEE oa IAE. Aeiaaaeaii o?niee ei?aeyoe?eiee
ca’ycie i?ae i?e?inoii ??aiy CD95+-ee?oei i?ae /an eo?no e?eoaaiiy ?
na?aaeiueith o?eaae?noth ?ai?n??. Iieacaii, ui ?acoeueoaoeaia e?eoaaiiy
oai?eo ia OEE c ?ioiieie oneeaaeiaiiyie i?ecaiaeeoue aei c?inoaiiy
iiioeyoe?? O-e?ioioeeo?a ? a?aeiiaeaiiy O-ee?oeiii? ?ioii?aaoeyoe??.
Aeyaeai? a?aei?iiino? ?ioiioaiioei?/ii? oa?aeoa?enoeee e?ioioeeo?a
ia?eoa?e/ii? e?ia? oai?eo ia OEIC c ?ioiieie oneeaaeiaiiyie a i?ioean?
??cieo noai oa?ai?? iiaeooue neoaoaaoe iniiaith aeey ?icoi?iiy iaoai?cio
ae?? ie?aieo e?eoaaeueieo caoiae?a.

I?AEOE*IA CIA*AIIss IAeA?AEAIEO ?ACOEUeOAO?A

Ia iniia? ni?anoaaeaiiy aoaeoeaiino? ie?aieo iaoiae?a e?eoaaiiy ?ioiieo
oneeaaeiaiue OEE oa ci?i oaiioei?/ii? oa?aeoa?enoeee e?ioioeeo?a
ia?eoa?e/ii? e?ia? oai?eo iaa?oioiaaia e?eoaaeueia oaeoeea i?e aeai?e
iaoieia??. ?ic?iaeaii i?aeoe/i? ?aeiiaiaeaoe?? uiaei canoinoaaiiy
ie?aieo noai oa?ai?? o oai?eo ia OEE c ?ioiieie oneeaaeiaiiyie c
o?aooaaiiyi ee?i?/ieo i?iya?a caoai?thaaiiy oa ci?iaie ?ioiioaiioei?/ii?
oa?aeoa?enoeee e?ioioeeo?a. Iaa?oioiaaii aeioe?euei?noue i?iaaaeaiiy
nieaiaeoii?? o oai?eo ia OEIC, ui i?io?eathoue c ?ioiieie
oneeaaeiaiiyie.

INIAENOEE AIANIE CAeIAOAA*A

Aaoi?ii naiino?eii i?iaaaeai? aiae?c aeooaeueiino? ? nooiaiy aea/aiiy
oaie ?iaioe, oa?aeoa?enoeea ianoaaeaieo oai?eo, aea?? ? ii?aoethaaiiy
iaoiaeee aeine?aeaeaiiy, ?ioiioaiioei?/i? aeine?aeaeaiiy ee?oei
ia?eoa?e/ii? e?ia?, noaoenoe/iee aiae?c iaoa??aeo. Aeyaeai?
caeiiii??iino? noi?ioeueiaaii o aeniiaeao.

AI?IAAOe?ss ?ACOEUeOAO?A AeENA?OAOe??

?acoeueoaoe aeine?aeaeaiue iieeaaeai? a iniiao ?ioi?iaoe?eiiai eenoea
«Aeeoa?aioe?eia ae?aaiinoeea aooi?ioiieo ? iaoaieanoe/ieo aaiioeeoiiai?e
o oai?eo o?ii?/iith e?ioi?aeiith eaeeai??th» (Ee?a, 1995),
aeiiia?aeaeenue ia Y eiia?an? na?oiai? oaaea?aoe?? Oe?a?inueeeo
e?ea?nueeeo oiaa?enoa (Aei?i?iiao?ianuee, 1994 ?.), 3 Oe?a?inueeiio
c’?cae? aaiaoieia?a ? o?ainooc?ieia?a (Noie, 1995), XIII Meeting Intern.
Soc. Haematology (European & African Division) (Istanbul, Turkiye,
1995), YI eiia?an? na?oiai? oaaea?aoe?? Oe?a?inueeeo e?ea?nueeeo
oiaa?enoa (Iaeana, 1996), 40th Annual Meeting of the GTH (Gesellschaft
fr Thrombose- und Hmostaseforschung) (Basel, 1996), I I?aeia?iaeiiio
eiia?an? iieiaeeo a/aieo (Oa?iii?eue, 1997), XIV Meeting of the Int.
Soc. Haematology (Stockholm, 1997), 4th Int. Symp. on Clinical
Immunology (Amsterdam, 1997), XVII Zjazd Polskiego Towarzystwa
Hematologow i Transfuzjologow (Krakow, 1997), Conf. “B-cell
Lymphoproliferative Disorders: contributions of molecular and cell
biology to understanding and treatment” (New York, 1998),
iaoeiai-i?aeoe/i?e eiioa?aioe?? iieiaeeo a/aieo oa oao?aoe?a «No/ani?
i?iaeaie aaiaoieia?? oa o?ainooc?ieia??» (Ee?a, 1998), Frhjahrstagung
1998 der sterreichischen Gesellschaft fr Hmatologie und Oncology (Baden
bei Wien, Austria, 1998), III Scientific and Educational Conf. “Chronic
Lymphocytic Leukaemias“ (Pu?awy, Poland, 1998). Iniiai? iieiaeaiiy
aeena?oaoe?? ai?iaaaeaeaii a i?aeoeeo aaiaoieia?/iiai a?aeae?eaiiy 5-i?
ee?i?/ii? e?ea?i? i.Eueaiaa, eiinoeueoaoeaii? iie?ee?i?ee Euea?anueeiai
o?e?aeo Ee?anueeiai IAe? aaiaoieia?? oa ia?aeeaaiiy e?ia?,
aaiaoieia?/iiai eaa?iaoo eiinoeueoaoeaii? iie?ee?i?ee Euea?anueei?
iaeanii? ee?i?/ii? e?ea?i?.

IOAE?EAOe??

?acoeueoaoe aeena?oaoe?? iioae?eiaaii o 4 noaooyo o iaoeiaeo aeo?iaeao,
13 oacao c’?cae?a ? eiioa?aioe?e oa a ?ioi?iaoe?eiiio eenoeo.

IANssA ? NO?OEOO?A AeENA?OAOe??

Aeena?oaoe?y aeeeaaeaia ia 174 noi??ieao iaoeiiieno, c ieo 112 noi??iie
oaenoo, 15 noi??iie caeiathoue oaaeeoe?, 7 noi??iie — ?ethno?aoe??, 40
noi??iie — nienie e?oa?aoo?e. ?iaioa neeaaea?oueny c? anooio, iaeyaeo
e?oa?aoo?e, i’yoe ?icae?e?a aeanieo aeine?aeaeaiue, aeniiae?a, nieneo
aeei?enoaieo aeaea?ae, yeee i?noeoue 369 aeaea?ae. ?iaioa ?ethno?iaaia
28 oaaeeoeyie oa 7 ?enoieaie.

CI?NO ?IAIOE

IAOA??AE ? IAOIAeE AeINE?AeAEAIIss

I?iaaaeaii ?ioiioaiioei?/ia ianoaaeaiiy 67 oai?eo o?ii?/ieie
e?ioii?ie?oa?aoeaieie caoai?thaaiiyie, ia?aa?a yeeo oneeaaeieany
?ioiieie oeeoiiai?yie. An? oai?? ia?aaoaaee ia noaoe?iia?iiio e?eoaaii?
a aaiaoieia?/iiio a?aeae?eaii? 5-i? ee?i?/ii? e?ea?i? i.Eueaiaa,
ee?i?/ii? aace Euea?anueeiai o?e?aeo Ee?anueeiai iaoeiai-aeine?aeiiai
?inoeoooo.

Na?aaei?e a?e oai?eo aeiinea 57,6±1,0 ?ie?a. Na?aae ianoaaeaieo
iaoe??io?a 53 (c ieo 36 /ieia?e?a ? 17 ae?iie) no?aaeaeaee ia A-OEE ? o
14 iaoe??io?a (10 /ieia?e?a ? 4 ae?iee) aoea ae?aaiinoiaaia
iaaiaeaee?inueea e?ioiia (IAE). O an?o oai?eo aeine?aeaeoaaany
?ioiieia?/iee oaiioei e?ioi?aeieo ee?oei ia?eoa?e/ii? e?ia? a i?ioean?
e?eoaaiiy (aei ii/aoeo ? i?ney cae?i/aiiy oa?ai??). O 9 oai?eo
ianoaaeaiiy i?iaaaeaii aea?/? — a i?ioean? ??cieo iaoiae?a e?eoaaiiy.
Aeey ii??aiyiiy io?eiaieo aeaieo i?iaaaeaii ?ioiioaiioei?/ia ianoaaeaiiy
12 oai?eo ia OEE aac ?ioiieo oneeaaeiaiue (I-II no. caoai?thaaiiy ca
Rai) oa aeine?aeaeaiiy aoii?aeueiiai ?ioi?oaoo o 34 caei?iaeo in?a. A
caaaeueiiio i?iaaaeaii 164 ?ioiioaiioei?/i? aeine?aeaeaiiy.

A caeaaeiino? a?ae i?ecia/aii? oa?ai?? aeae?eaii 7 a?oi oai?eo ia OEE:

1) 13 oai?eo iaea?aeoaaee i?aaei?cieii (Pr) a na?aaei?e aeic? 1-2 ia/ea
iane/aeiao;

2) 11 oai?ei iaeii/anii c i?aaei?cieiiii o noaiaea?oi?e aeic? aaiaeeee
a?ie?enoei (Vr) 2 ia iaeei ?ac ia oeaeaeaiue i?e eo?nia?e aeic? 6 ia;

3) 8 oai?eo io?eioaaee oei?aiaooeee (Chl) a aeic? 0,15-0,2 ia/ea
iane/aeiao aei 200-300 ia ia eo?n e?eoaaiiy a eiia?iaoe?? c
i?aaei?cieiiii;

4) 8 oai?ei e?eoaaiiy i?ecia/aeinue ca noaiith NI? (2 ia a?ie?enoeio
aioo??oiueiaaiii 1-ee aeaiue, oeeeeioinoai 750 ia/i2 aioo??oiueiaaiii
1-e aeaiue, i?aaei?cieii 40 ia/i2 per os i?ioyaii 5 aei?a);

5) 9 oai?ei ia oii? e?eoaaiiy i?aaei?cieiiii i?ecia/aeenue aeoeaaoi?e
O-nenoaie ?ioi?oaoo (Thy) (O-aeoea?i, oeiae?i) a aeic? 1,0 ie i?aia?aoo
aioo??oiueii’ycaai (10 ?i’?eoe?e ia eo?n);

6) eaeeaieaciaoa?ac (LPF) ia oii? e?eoaaiiy i?aaei?cieiiii i?iaiaeeany o
7 oai?eo. Eo?n e?eoaaiiy neeaaeaany ?c 2-7 naain?a eaeeaieaciaoa?aco c
aeaeaeaiiyi a na?aaeiueiio 800-1200 ie ieacie ? 50-140 ie eaeeiiane;

7) nieaiaeoii?y (Spl) i?iaaaeaia o 7 oai?eo ia OEE. Aei iia?aoe?? ? a
i?neyiia?aoe?eiiio ia??iae? oai?? iaea?aeoaaee i?aaei?cieii a aeic? 1-3
ia/ea iane a caeaaeiino? a?ae aaiiaeeiai?ee.

Oai?ei ia IAE (7 oai?eo c ?ioiieie oneeaaeiaiiyie ? 7 oai?eo aac ?ioiieo
oneeaaeiaiue) i?iaaaeaia nieaiaeoii?y. Iieacaie aei nieaiaeoii?? aoee
cia/ia nieaiiiaaae?y, ?cieueiaaia o?aaeaiiy naeac?iee, iaaoaeoeai?noue
eiina?aaoeaiiai aai oeeoinoaoe/iiai e?eoaaiiy, iino?eii ?aoeeaeeaoth/ee
ia?aa?a ?ioiieo oneeaaeiaiue.

O ?iaio? aeei?enoiaoaaeenue caaaeueiiee?i?/i?, aaiaoieia?/i?,
a?io?i?/i?, na?ieia?/i? oa ?ioiieia?/i? iaoiaee aeine?aeaeaiiy.

O a?oio ?ioiieia?/ieo iaoiae?a aoiaeeee:

1. Aecia/aiiy aeeoa?aioe?eieo aioeaai?a ia iaia?ai? e?ioi?aeieo ee?oei
ca aeiiiiiaith iiiieeiiaeueieo aioeo?e (IEAO) na??? ?II (io?eiaieo
N.I.Neaei?aiei ? ni?aaao. a ?inoeooo? aenia?eiaioaeueii? iaoieia??,
iieieia?? oa ?aae?ia?ieia?? ?i.?.?.Eaaaoeueeiai IAI Oe?a?ie), na??? ?EI
(io?eiaieo A.TH.Aa?eoi?eiaei ? ni?aaao. a ?inoeooo? ee?i?/ii? iieieia??
?IIOe AI ?in??), na??? EO (io?eiaieo I.A.O?eaoiaei ? ni?aaao. a
?inoeooo? ?ioiieia?? IIC ?in??) oa na??? ANA (io?eiaieo O.?.Aoee/iaith ?
ni?aaao. a ?in?enueeiio aaiaoieia?/iiio iaoeiaiio oeaio??). Iaiaeue
aeeth/aea 29 IEAO.

Aeine?aeaeaiiy ?ioiioaiioeio e?ioi?aeieo ee?oei i?iaiaeeeinue iai?yiei
?ioiioethi?anoeaioiei iaoiaeii a iiiioa?? ee?oei, i?ee??ieaieo aei neea
ca aeiiiiiaith iie?-L-e?ceio (o??ia «Sigma»). sse aoi?eiia ne?iaaoea
canoiniaoaaeenue F(ab)2-o?aaiaioe aioeo?e aei ?ioiiaeiaoe?i?a a?ei?
ieo?, iii?/ai? oethi?i?cio?ioe?aiaoii, io?eiai? a IAI «I?aia?ao» i?e
Ieaeiuei-Iiaai?iaenueeiio IAe?A?I.

E?ioi?aei? ee?oeie iaea?aeoaaee c aaia?ei?ciaaii? aaiicii? e?ia? ca
iaoiaeii aeeoa?aioe?eiaaiiai oeaio?eooaoaaiiy a a?aae??io? u?eueiino?
aa?ia?ao?io-o?eieo (d=1,077) (E.A.Oaeoaoe, A.A.Aaaeaeei, 1973).
A?aeiinio e?euee?noue aioeaaiiiceoeaieo iiiiioeeaa??a i?ae?aoiaoaaee ia
100-200 ee?oei, aeei?enoiaoth/e ethi?ianoeaioiee i?e?ineii «Ethiai ?-8».

2. Aecia/aiiy eiioeaio?aoe?? ne?iaaoeiaeo ?ioiiaeiaoe?i?a eean?a G, A, M
iaoiaeii ?aae?aeueii? ?ioiiaeeooc??.

3. Aecia/aiiy ??aiy oee?eoethth/eo ?ioiieo eiiieaen?a o ne?iaaooe?
e?ia?.

Io?eiai? ?acoeueoaoe ioe?ithaaee iaoiaeii aa??aoe?eii? noaoenoeee
(I.I.Aea?ea/, 1963).

?ACOEUeOAOE AeINE?AeAEAIUe OA ?O IAAIAI?AIIss.

A i?ioean? e?eoaaiiy i?aaei?cieiiii (Pr) ?ai?n?y ?ioiiiai oneeaaeiaiiy
?icaeioeanue o 54% oai?eo ia OEE, a ?? o?eaae?noue a na?aaeiueiio
aeiineea (5,4±0,9) i?n. I?ae ae??th i?aaei?cieiio ia A-ee?oeiao
ciaiooaaeanue aeni?an?y ia?ea??a aeic??eeo ee?oei CD20, CD72 (oaae.1).
Iaeii/anii c?inoaa ??aaiue aeni?an?? aeoeaaoe?eieo ia?ea??a CD25R i
CD11b (oaae.2).

Ia oii? ?noioiiai cieaeaiiy /enea aeic??eeo CD3+ O-ee?oei aeyaeaii
i?aeaeuaiiy ??aiy CD4+ O-aaeia??a ? a?eueo cia/iee ??no CD8+-ee?oei.
Ni?aa?aeiioaiiy CD4+/CD8+ i?e oeueiio aeinoia??ii ciaiooaaeinue. ??aaiue
CD16+-ee?oei (NK-ee?oei) i?ney e?eoaaiiy i?aaei?cieiiii cia/ii
i?aeaeuoaaany.

E?eoaaiiy ?ioiieo oneeaaeiaiue OEE a?ie?enoeiii (Vr) ? i?aaei?cieiiii
i?eaiaeeei aei ?ai?n?? o 73% oai?eo o?eaae?noth (13,5±3,0) i?n.
Iieacieeii iiceoeaiiai oa?aiaaoe/iiai aieeao a?ie?enoeio ia eaeeai?/i?
A-ee?oeie aoei aeinoia??ia cieaeaiiy eeiiaeueiiai aenoeano. Aaaeeeaei
oaeoi?ii aoaeoeaiino? a?ie?enoeio i?e OEE ? i?aeaeuaiiy ??aiy aeni?an??
ia eaeeai?/ieo ee?oeiao Fas-?aoeaioi?a (CD95) ye iane?aeie aeoeaaoe??,
/a?ac ui aiie noathoue a?eueo /ooeeaeie aei ?iaeoeoe?? aiiioico
oeeoie?iaie.

I?ney e?eoaaiiy a?ie?enoeiii c i?aaei?cieiiii aeyaeaii c?inoaiiy
e?eueeino? CD3+-ee?oei oa nooo?aa ca?eueoaiiy e?eueeino? CD4+-ee?oei, o
ca’yceo c /ei ni?aa?aeiioaiiy Th/Ts ii?iae?coaaeinue. Eo?n e?eoaaiiy
i?aia?aoii aee?eoth/i? ae?? c a?oie acioenoeo ?i?eo?a — oei?aiaooeeeii
(Chl) — oa i?aaei?cieiiii coiiaea aeieeiaiiy ?ai?n?? ?ioiiiai
oneeaaeiaiiy o 75% oai?eo, iaeiae o?eaae?noue ?? aoea ei?ioeith —
(6,1±1,3) i?n. ?ioiioaiioei?/ii aeyaeaii cieaeaiiy ??aiy aeni?an??
A-ee?oeiieo aioeaai?a CD20, CD37 i CD72. ?noioii i?aeaeuoaaany ??aaiue
aeni?an?? o?eueee CD11b, a a?aenioie ee?oei, ye? ?aaaoaaee c IEAO
?II-38, eio?a aeyaey? aioeaai i?ie?oa?oth/eo ee?oei Ki67, cieaeoaaany.
Oei?aiaooeee i?eai?/o? i?ie?oa?aoeaio ? i?oioe/io aeoeai?noue
eaeeai?/ieo ee?oei (C.I.Aoeeeia, 1991), ui ie i?aeoaa?aeeee
?ioiioaiioei?/ieie aeine?aeaeaiiyie.

Eo?n e?eoaaiiy oei?aiaooeeeii oa i?aaei?cieiiii i?ecaiaeea aei c?inoaiiy
noaiiioeyoe?e O-aaeia??a oa O-noi?ani??a i?eaeecii a iaeiaeia?e i???,
oae ui ni?aa?aeiioaiiy CD4+/CD8+ ?noioii ia ci?ithaaeinue. I?aeaeuoaaany
??aaiue CD16+ NK-ee?oei.

I?ney eo?no iie?o?i?ioa?ai?? ca noaiith NI? iiaia ?ai?n?y ?ioiiiai
oneeaaeiaiiy ?icaeioeanue o 75% oai?eo, a na?aaeiy o?eaae?noue ?ai?n??
?ioiiiai oneeaaeiaiiy aoea (10,4±3,2) i?n. Aeia?ee ee?i?/iee aoaeo
i?ia?aie NI? noi?iaiaeaeoaaany ae?aaeaieie ci?iaie a aeni?an??
A-ee?oeiieo ia?ea??a oa cieaeaiiyi aaniethoii? e?eueeino? e?ioioeeo?a ia
15,2%. A?aecia/aii ae?aaeaia cieaeaiiy a?aenioea HLA-Dr+-, CD20+-,
CD21+-, CD22+-, sIgM+-, CD37+-, ?II-10+-, CD72+- oa CD76+-ee?oei.
Iaeii/anii anoaiiaeaii ae?aaeai? iciaee aeoeaaoe?? eaeeai?/ieo A-ee?oei,
ia iaia?ai? yeeo c??n ??aaiue aeni?an?? a?eueoino? aeine?aeaeaieo
aeoeaaoe?eieo ia?ea??a: CD25R, CD11b, CD95 i ia?ea?a A-aeano?a
aioeaaicaeaaeii? noaae?? aeic??aaiiy (i?ie?oa?oth/eo ee?oei), yeee
?aaao? c IEAO ?II-3.

I?ney e?eoaaiiy ca noaiith NI? aeni?an?y iaeaea an?o O-ee?oeiieo
aioeaai?a (CD2, CD7, CD3, CD4) ia?inoaea, ie??i CD8, caaaeyee /iio
ni?aa?aeiioaiiy CD4+/CD8+ oaae ca?eueooaaeinue, aeinyaath/e ii?iaeueieo
aaee/ei.

Oaaeeoey 1

Aeni?an?y iniiaieo A-ee?oeiieo aioeaai?a ia iaia?ai? e?ioi?aeieo ee?oei
ia?eoa?e/ii? e?ia? oai?eo ia OEIC i?e ??cieo iaoiaeao e?eoaaiiy

Aioeaai HLADR CD20 CD21 CD22 CD5 CD37 CD72 ?II10 Pr aei73,5±2,8
43,3±5,6 49,2±2,5 51,0±5,4 69,5±2,3 58,3±8,4 48,1±5,4 38,3±3,1
i?ney74,0±1,9 28,7±4,6*44,9±3,2 50,8±5,6 69,2±2,8 51,6±8,2
30,0±4,8*41,7±2,9 Vr+Pr aei75,8±3,2 52,2±7,5 58,7±5,7 72,6±3,4 71,3±3,7
72,7±9,5 60,1±5,3 44,1±6,9 i?ney61,9±5,3*46,2±9,4 41,0±6,0*59,9±7,9
63,5±3,9 64,9±6,0 53,5±6,7 41,3±6,9 Chl+Praei65,8±2,3 56,4±3,3 52,3±3,4
59,2±2,5 64,0±1,2 75,8±1,5 59,3±2,6 55,3±3,3 Oai?? ia OEE i?ney68,3±2,5
43,7±3,5*49,4±3,8 56,2±3,8 66,3±1,8 64,0±4,4*49,8±2,0*50,7±3,2 c
?ioiieieCOP aei78,9±1,4 50,7±1,6 52,2±1,9 60,0±3,0 61,6±1,9 51,3±1,8
52,1±1,7 48,2±1,2

oneeaaeiaiiyie i?ney68,8±1,9*44,3±1,9*46,6±1,1*50,8±2,0*65,9±2,1
45,5±1,3*45,8±1,9*42,2±1,2*Thy+Praei81,5±2,2 57,8±8,0 47,3±7,7 75,6±4,3
59,8±0,8 83,3±4,2 55,3±8,0 44,7±0,3 i?ney71,3±6,3 55,0±6,0
29,7±2,9*51,4±0,5*61,3±8,5 82,4±3,7 45,3±4,1 48,5±8,6 LPF+Praei67,6±3,0
55,2±3,9 49,3±6,1 60,2±5,3 65,3±3,6 67,2±5,6 46,0±5,5 33,5±5,5
i?ney57,6±4,9 49,0±4,7 42,3±4,6 58,4±8,4 54,3±8,5 43,8±8,1*46,0±2,0
43,5±1,5 Spl+Praei79,2±1,8 58,1±3,7 52,8±3,0 63,8±3,5 67,0±3,4 74,7±4,8
61,4±3,8 58,8±5,5 i?ney72,6±2,2*40,8±5,4*40,6±2,8*56,5±2,5
54,2±1,6*61,6±2,6*49,5±2,9*43,4±3,5*Oai?? ia IAESpl+Praei65,4±2,5
56,3±2,6 39,9±3,1 57,6±4,4 — 72,4±4,1 46,0±1,2 40,1±7,0 aac
oneeaaeiaiuei?ney65,9±4,8 51,0±3,7 31,7±2,6*56,3±4,4 — 63,0±3,2
40,3±1,6*39,0±5,3

Spl+Praei70,4±4,6 65,4±3,8 33,6±5,5 62,6±8,3 — 73,4±4,6 49,8±2,1
41,6±4,0 i?ney66,2±7,6 49,7±4,7*28,0±4,1 58,4±2,1 — 58,8±8,7
41,7±1,7*28,6±2,7*

I?ei?oea. * — noaoenoe/ii aeinoia??ia ??cieoey i?ae iieacieeaie aei oa
i?ney e?eoaaiiy (p<0,05). Oaaeeoey 2 Aeni?an?y iniiaieo aeoeaaoe?eieo oa O-ee?oeiieo aioeaai?a ia iaia?ai? e?ioi?aeieo ee?oei ia?eoa?e/ii? e?ia? oai?eo ia OEIC i?e ??cieo iaoiaeao e?eoaaiiy Aioeaai CD25RCD11bCD95CD2CD3CD7CD4CD8CD4/CD8Pr aei 6,6±1,3 3,0±1,0 6,3±1,5 3,2±0,5 8,3±1,0 5,7±1,9 6,6±0,3 2,8±0,3 2,6±0,2 i?ney10,7±0,8* 9,4±2,7* 7,2±1,5 3,3±0,7 5,4±0,9*4,7±1,8 8,5±0,4* 4,9±0,4* 1,9±0,2*Vr+Praei 4,2±0,6 2,2±0,8 10,6±3,5 4,0±0,7 6,4±0,5 3,8±1,2 6,2±0,6 3,2±0,4 2,0±0,1 i?ney 6,3±0,7* 6,1±1,3*20,3±2,6* 5,0±1,8 10,0±1,2*5,9±1,1 9,8±1,4*4,0±0,6 2,5±0,1*Oai?? ia OEEChl+Praei 9,2±1,1 3,0±0,4 6,0±1,0 3,4±0,7 9,1±0,4 4,8±0,7 6,1±0,6 3,0±0,2 2,0±0,1 c ?ioiieiei?ney11,8±1,2 5,5±0,5* 7,7±1,5 5,0±0,9 9,6±1,0 4,7±0,8 8,6±0,6* 4,3±0,4*2,1±0,2     oneeaaeiaiiyieCOPaei 5,5±1,0 2,6±0,4 6,0±0,9 3,0±0,6 4,4±0,9 3,0±0,6 6,4±0,4 3,0±0,3 2,2±0,2 i?ney 9,2±0,8* 4,3±0,3*11,3±1,4* 5,3±0,7* 8,1±1,3* 5,0±0,5* 9,1±0,5*3,4±0,1 2,7±0,1*Thy+Praei 3,0±2,0 0,8±0,3 8,5±3,6 5,7±2,0 5,3±1,7 4,9±1,9 4,9±1,2 3,3±0,6 1,3±0,3 i?ney4,0±2,0 1,4±0,5 5,5±2,8 4,0±1,0 4,8±1,2 9,9±1,3* 9,4±1,6*4,3±0,9 2,6±0,5*LPF+Praei9,7±1,8 3,8±1,2 13,5±1,4 10,5±5,5 4,3±1,5 2,8±0,7 6,1±1,3 3,9±0,9 1,7±0,1 i?ney15,3±0,8* 5,0±0,8 9,0±3,8 10,0±5,0 10,0±3,6* 5,7±1,0* 9,9±1,8 4,3±0,8 2,4±0,2*Spl+Praei17,4±1,7 1,8±0,7 3,5±0,7 3,3±0,8 10,8±4,06,8±2,4 7,5±0,9 4,3±0,8 1,8±0,2 i?ney25,8±2,3* 2,3±0,3 10,2±2,3* 7,8±1,5*13,2±2,17,4±0,7 11,2±0,7* 6,6±0,5*1,8±0,2 Oai?? ia IAESpl+Praei16,4±2,4 13,7±2,724,2±2,6 5,3±2,3 16,3±4,74,4±0,8 7,6±0,4 4,6±0,3 1,7±0,1 aac oneeaaeiaiuei?ney14,8±1,2 18,6±2,334,0±1,8* 3,7±0,7 18,0±4,0 7,7±0,6* 9,9±1,1 4,3±0,4 2,4±0,2* Spl+Praei10,0±3,0 24,6±6,5 4,4±1,1 3,2±0,7 8,8±1,5 7,4±1,3 7,6±1,0 4,3±0,8 1,9±0,2i?ney18,2±1,2*23,0±12,111,6±2,4*9,7±2,5*14,5±3,2 7,6±1,6 12,0±1,1*5,2±0,5 2,3±0,1* I?ei?oea. * — noaoenoe/ii aeinoia??ia ??cieoey i?ae iieacieeaie aei oa i?ney e?eoaaiiy (p<0,05). I?e canoinoaaii? a a?oi? oai?eo ia OEE c ?ioiieie oneeaaeiaiiyie ai?iii?a oeiono (Thy) c i?aaei?cieiiii ?ai?n?y ?ioiiiai oneeaaeiaiiy ?icaeioeanue o 50% oai?eo, a ?? o?eaae?noue ((4,11±0,84) i?n) ia a?ae??ciyeanue a?ae a?oie oai?eo, eio?? io?eioaaee o?eueee i?aaei?cieii. Ai?iiie oeiono aeeeeeaee o oai?eo ia OEE iiceoeai? ci?ie a iiioeyoe?? O-e?ioioeeo?a: c?inoaea aeni?an?y iaea?eueo ?aiiueiai O-ee?oeiiiai ia?ea?a CD7, i?aeaeuoaaany a?aenioie CD4+-ee?oei, ui i?ecaiaeeei aei ?noioiiai ca?eueoaiiy ?ioii?aaoeyoi?iiai ?iaeaeno (ni?aa?aeiioaiiy Th/Ts). Ia iiioeyoe?? eaeeai?/ieo A-ee?oei aeyaeaii cieaeaiiy aeni?an?? ia?ea??a a?eueo c??eeo A-e?ioioeeo?a CD21 i CD22. Ia anoaiiaeaii iiyae ia A-ee?oeiao aeoeaaoe?eieo ia?ea??a, ie??i CD38, ??aaiue aeni?an?? yeiai iineeeany. I?ney eo?no e?eoaaeueiiai eaeeaieaciaoa?aco (LPF) ia?aaaaeii ?icaeaaeanue /anoeiaa ?ai?n?y ?ioiiiai oneeaaeiaiiy o 86%, o?eaae?noue yei? aoea (5,4±1,4) i?n. A e?ioe? eo?no naain?a eaeeaieaciaoa?aco aaniethoia e?euee?noue e?ioioeeo?a e?ia? cieaeoaaeanue ia 35,7%. ?ioiioaiioei?/ia oa?aeoa?enoeea eaeeai?/ieo A-ee?oei ia ci?ithaaeanue, ca aeiyoeii ciaioaiiy aeni?an?? CD37, aecia/aiiai IEAO ?EI-66. Ca?eueooaaeinue /enei CD25R+-ee?oei, ui aeaco? ia i?aeaeuaiiy /ooeeaino? A-ee?oei aei IL-2, yeee caoeua? ?o a?ae aiiioico (A.P.Jewell, 1996). Eaeeaieaciaoa?ac i?eaiaeea aei ?noioiiai c?inoaiiy a?aenioea O-e?ioioeeo?a ca aeni?an??th aioeaai?a CD3 oa CD7. Ni?aa?aeiioaiiy CD4+/CD8+ i?ney eo?no e?eoaaiiy i?aeaeuoaaeinue ca ?aooiie ca?eueoaiiy e?eueeino? O-aaeia??a. I?ney nieaiaeoii?? o an?o oai?eo ianooiaea iiaia ?ai?n?y ?ioiiiai i?ioeano, o?eaae?noue yei? a na?aaeiueiio aeiineea (17,2±3,8) i?n. A e?oa?aoo?? iienaia a?aeiia?aeue ia nieaiaeoii?th o oai?eo ia OEE: aeinoia??ia i?iaeiaaeaiiy aeaeeaaiiy oai?eo ii??aiyii c o?i?ioa?ai??th oa ca?eueoaiiy e?eueeino? eaeeioeeo?a ia?eoa?e/ii? e?ia? (J.C.Cusack Jr. ? ni?aaao., 1997). I?ney nieaiaeoii?? (Spl) o oai?eo ia A-OEE, iacaaaeath/e ia i?aeaeuaiiy aaniethoii? e?eueeino? e?ioioeeo?a, aecia/aeinue aeinoia??ia cieaeaiiy ??aiy aeni?an?? ia A-ee?oeiao aioeaai?a HLA-Dr, CD20, CD21, CD37, CD72, CD76 oa e?eueeino? ee?oei, ui aca?iiae?yee c A-e?i?eiei IEAO ?II-10. Iniaeeao oaaao i?eaa?oa? ?noioia ciaioaiiy a?aenioea CD5+-ee?oei, ye? oa?aeoa?ecothoue eaeeai?/io iiioeyoe?th i?e A-OEE. Aeyaeaii iciaee aeoeaaoe?? eaeeai?/ieo A-ee?oei i?ney aeaeaeaiiy naeac?iee, cie?aia, aeinoia??ii i?aeaeueeanue ia ieo aeni?an?y ?aoeaioi?a IL-2 (CD25R) oa Fas-?aoeaioi?a (CD95). I?ney nieaiaeoii?? niinoa??aaeinue i?aeaeuaiiy ??aiy aeni?an?? O-ee?oeiieo aioeaai?a CD2, CD4, CD8, ni?aa?aeiioaiiy Th/Ts caeeoaeinue aac ?noioieo ci?i. E?euee?noue CD16+-ee?oei c?inoaea a?eueoa, i?ae oaea?/?. Ie i?iaaee aiae?c ee?i?/ieo ?acoeueoao?a oa ci?i oaiioeio ee?oei e?ia? i?ney aeaeaeaiiy naeac?iee o 14 oai?eo ia A-ee?oeii? IAE iecueeiai nooiaiy ceiye?niino?. O 7 oai?eo nieaiaeoii?y i?iaaaeaia a ca'yceo c? cia/iith nieaiiiaaae??th ? iniiaiith eieae?caoe??th iooeeiiiai i?ioeano a naeac?ioe?, a o 7 oai?eo ia IAE iieacii aeey iia?aoeaiiai e?eoaaiiy aoee ?ioii? oneeaaeiaiiy oa ianeaia nieaiiiaaae?y. O an?o oai?eo a e?ia? aoea aeyaeaia iiiieeiiaeueia iiioeyoe?y A-ee?oei c eaeeai?/iith ea?oeiith e?ia? aai aac ia?. I?ney nieaiaeoii?? a iaio a?oiao iaoe??io?a ianoaa aeineoue o?eaaeee aac?aoeeaeeaiee ia??iae. I?e ?ioiieo oneeaaeiaiiyo IAE na?aaeiy o?eaae?noue ?ai?n?? neeaaeaea (18,8±3,9) i?n. O oai?eo ia IAE aac oneeaaeiaiue i?ney nieaiaeoii?? aeyaeaii o?eueee cieaeaiiy aeni?an?? aioeaai?a CD21 oa CD72 ia A-ee?oeiao. O oai?eo ia IAE c ?ioiieie oneeaaeiaiiyie i?ney iia?aoe?? ia oii? ca?eueoaiiy e?eueeino? e?ioioeeo?a o ia?eoa?e/i?e e?ia? ianooiaee a?eueo ?noioi? c?ooaiiy a iiioeyoe?? A-ee?oei: ciaiooaaeanue aeni?an?y aioeaai?a CD20, CD21, CD37, CD72 oa e?euee?noue ee?oei, ui ?aaaothoue c ?II-10. A iaio a?oiao oai?eo ia IAE niinoa??aaeeny yaeua aeoeaaoe?? A-ee?oei. ?noioii c?inoaea e?euee?noue ee?oei, ia yeeo aeyaeyee Fas-aioeaai (CD95), a o iaoe??io?a c ?ioiieie oneeaaeiaiiyie — iaeii/anii ? aeni?an?y CD25R. A?ieia?/ia cia/aiiy oeeo ci?i A-ee?oei i?e IAE i?ney nieaiaeoii?? oaea ae, ye i?e OEE: e?ioiii? ee?oeie noathoue /ooeea?oeie aei ?iaeoeoe?? aiiioico /a?ac Fas-?aoeaioi?. I?ney nieaiaeoii?? anoaiiaeaii oaeiae aeaye? ci?ie a aeni?an?? O-ee?oeiieo aioeaai?a. O oai?eo ia IAE aac oneeaaeiaiue c?inoaea aeni?an?y aioeaaia CD7. E?euee?noue O-aaeia??a iaea oaiaeaioe?th aei ca?eueoaiiy, yea iaeiae ia aeinyaea noaoenoe/ii aeinoia??iiai ??aiy (p>0,05), i?ioa ni?aa?aeiioaiiy CD4+/CD8+ i?aeaeuoaaeinue.

O oai?eo ia IAE c ?ioiieie oneeaaeiaiiyie i?ney iia?aoe?? c?inoaei /enei
O-ee?oei, ia yeeo aeyaeyeenue CD2 oa CD4 aioeaaie (p<0,05). A?aeiia?aeii ca?eueooaaeinue ni?aa?aeiioaiiy CD4+/CD8+. I?aeaeuaiiy ??aiy CD16+ NK-ee?oei i?ney nieaiaeoii?? niinoa??aaee a a?oi? oai?eo ia IAE, oneeaaeiaieo ?ioiieie i?ioeanaie. Iniaeeaeo c?ooaiue a iieacieeao aoii?aeueiiai ?ioi?oaoo (eiioeaio?aoe?? ?ioiiaeiaoe?i?a G, A, M oa Oe?E) a caeaaeiino? a?ae i?ia?aie e?eoaaiiy ie ia niinoa??aaee, e??i cieaeaiiy ??aiy IgA i?ney i?ecia/aiiy i?aaei?cieiio oa oei?aiaooeeeo c i?aaei?cieiiii, ui iienaii a e?oa?aoo?? (A.A.Ai?aoeeee, 1985). I?aenoiiaoth/e iane?aeee i?iaaaeaieo aeine?aeaeaiue, iiaeia c?iaeoe aeniiaie, ui canoiniaai? noaie e?eoaaiiy ?ioiieo oneeaaeiaiue OEE a?ae??ciythoueny ca nai?th aoaeoeai?noth, i?e/iio ?nio? caeaaei?noue i?ae ee?i?/iei ?acoeueoaoii oa ci?iaie, ye? i?ioiaeyoue a aeni?an?? iiaa?oiaaeo ia?ea??a i?ney eo?no oa?ai??. Ie anoaiiaeee, ui aiane?aeie iioeiaeaeoth/i? ae?? oeeoinoaoe/ieo cania?a /e aieeao a?ieia?/ieo oaeoi??a ia ee?oeii? no?oeoo?e a?aeaoaathoueny e?euee?ni? ? ye?ni? ci?ie oaiioei?/ii? oa?aeoa?enoeee eaeeai?/ieo A-ee?oei. E?euee?ni? ci?ie oi?eathoueny ??aiy aeni?an?? A-ee?oeiieo ia?ea??a. Aeyaeaii caeiiii??i?noue: /ei aeua aoaeoeai?noue i?ia?aie oa?ai??, oei ieae/a aeni?an?y a?eueoi? e?eueeino? A-ee?oeiieo ia?ea??a. Aei ye?nieo ci?i A-ee?oei ie a?aeianee iiyao (/e ca?eueoaiiy aeni?an??) aeoeaaoe?eieo ia?ea??a, ye? na?ae/aoue, ui i?ae aieeaii e?eoaaiiy /anoeia eaeeai?/ieo ee?oei aeeoa?aioe?th?oueny, ? oei naiei aiie noathoue a?eueo aeinooiieie iioeiaeaeoth/?e ae?? oeeoinoaoee?a oa ?iaeoeoe?? aiiioico. I?eaa?oa? oaaao oa, ui iae/ano?oa ia eaeeai?/ieo ee?oeiao ca?eueooaaeanue aeni?an?y CD25R, ?aoeaioi?a IL-2, yeee caoeua? ee?oeie a?ae caaeaae? (aiiioico). Iaeiae iaeaaaeeea?oa ee?i?/ia cia/aiiy ia? i?aeaeuaiiy i?ney eo?no oa?ai?? e?eueeino? ee?oei, ia yeeo aeyaey?oueny Fas-?aoeaioi? (CD95), e?aoaaiiy yeiai oaeoi?ii iae?ico iooeei caionea? i?ia?aio aiiioico. Caaaeii, CD95 ia ? oa?aeoa?iei aeey e?ioi?aeieo ee?oei ? c’yaey?oueny ia iaia?ai? i?e ?o aeoeaaoe?? ? aeeoa?aioe?aoe??. Iaie aeiaaaeaii a aeai?e ?iaio?, ui c?inoaiiy e?eueeino? CD95+-ee?oei ianooia? i?ney i?ia?ai e?eoaaiiy c aenieith oa na?aaeiueith ?acoeueoaoeai?noth, oiaoi i?ney nieaiaeoii?? ye o oai?eo ia OEE, oae ? i?e IAE, a oaeiae i?ney eo?no oa?ai?? a?ie?enoeiii c i?aaei?cieiiii oa ca noaiith NI?. O?niee ei?aeyoe?eiee ca'ycie (r=+0,788) niinoa??aaany i?ae i?e?inoii ??aiy CD95+-ee?oei i?ioyaii eo?no e?eoaaiiy ? na?aaeiueith o?eaae?noth ?ai?n??. E?eoaaiiy ?ioiieo oneeaaeiaiue OEE oa IAE i?ecaiaeeoue aei c?ooaiue a nenoai? O-ee?oei. Aiie iieyaathoue a ca?eueoaii? e?eueeino? O-ee?oei ca ??aiai aeni?an?? iaeiiai /e aeae?eueeio O-ee?oeiieo ia?ea??a (CD2, CD3, CD7), a oaeiae i?aeaeuaii? a?aenioea CD4+-ee?oei i?e a?eueoino? i?ia?ai, ca aeiyoeii eaeeaieaciaoa?aco. Iieaciee ni?aa?aeiioaiiy CD4+/CD8+ ia?aaaaeii i?aeaeuo?oueny, iacaeaaeii a?ae aoaeoeaiino? e?eoaaiiy. Ci?ie a nenoai? O-e?ioioeeo?a, ui aeieeathoue a ?acoeueoao? oa?ai??, i/aaeaeii, ia coiiaeai? i?yiei aieeaii oa?aiaaoe/ieo cania?a, a ? iane?aeeii ?ioii?aaoeyoi?ieo c?ooaiue ana?aaeei? ?ioiii? nenoaie, cie?aia ciaioaiiyi aieeao eaeeai?/ieo A-ee?oei. Aeyaeai? a aeai?e ?iaio? ?ioiioaiioei?/i? ci?ie ceiye?niiai eeiio A-ee?oei oa nenoaie O-e?ioioeeo?a neoaothoue iaa?oiooaaiiyi iaea?eueo ?aoe?iiaeueii? oaeoeee oa?ai?? ?ioiieo oneeaaeiaiue OEE oa IAE iecueeiai nooiaiy ceiye?niino?. AENIIAEE 1. I?iaaaeaiiy ??cieo i?ia?ai e?eoaaiiy o oai?eo ia o?ii?/io e?ioi?aeio eaeeai?th c ?ioiieie oneeaaeiaiiyie i?eaiaeeoue aei e?euee?nieo ? ye?nieo ci?i ?ioiioaiioei?/ii? oa?aeoa?enoeee ceiye?nieo A-ee?oei, ae?aaeai?noue yeeo ei?aeth? c aoaeoeai?noth oa?ai??. 2. Iaeaeuee i?ioeaio ?ai?n?e ? o?eaae?noue aac?aoeeaeeaiiai ia??iaeo ?ioiiiai oneeaaeiaiiy o oai?eo ia A-ee?oeiio o?ii?/io e?ioi?aeio eaeeai?th niinoa??aa?oueny i?ney nieaiaeoii??, ui ni?aiaaea? c iaea?eueo aaaiiei cieaeaiiyi ??aiy aeni?an?? a?eueoino? A-ee?oeiieo ia?ea??a, aeeth/ath/e a?aenioie CD5+-ee?oei, a ii??aiyii? c ?ioeie iaoiaeaie e?eoaaiiy, a oaeiae c?inoaiiyi aeni?an?? aeoeaaoe?eieo aioeaai?a ?, iniiaia, ca?eueoaiiyi aeni?an?? Fas-?aoeaioi?a (CD95). 3. O an?o oai?eo ia iaaiaeaee?inueeo e?ioiio i?ney nieaiaeoii?? ianoa? iiaia ?ai?n?y ?ioiiiai oneeaaeiaiiy o?eaae?noth 18,8 i?n, ciaioo?oueny /enei ee?oei, ui aeni?anothoue A-ee?oeii? aioeaaie, a aeni?an?y aeoeaaoe?eieo aioeaai?a c?inoa? — aaaiii ca?eueoo?oueny e?euee?noue CD95+-ee?oei. Iiae?ai? ci?ie ?ioiioaiioei?/ii? oa?aeoa?enoeee e?ioi?aeieo ee?oei oaeiae niinoa??aathoueny i?ney nieaiaeoii?? o oai?eo ia iaaiaeaee?inueeo e?ioiio aac ?ioiieo oneeaaeiaiue. 4. I?e canoinoaaii? a?ie?enoeio c i?aaei?cieiiii /e noaie NI? o 73-75 % oai?eo ia o?ii?/io e?ioi?aeio eaeeai?th ?icaeaa?oueny iiaia ?ai?n?y ?ioiiiai oneeaaeiaiiy o?eaae?noth (10,4±3,2) i?n oa (13,5±3,00) i?n a?aeiia?aeii, yea noi?iaiaeaeo?oueny ciaioaiiyi a?aenioea eaeeai?/ieo ee?oei ca ??aiai aeni?an?? cia/ii? /anoeie A-ee?oeiieo ia?ea??a, a oiio /ene? eeiiaeueiiai aenoeano eaeeai?/ieo A-e?ioioeeo?a (a?ie?enoei) oa sIgM+-ee?oei (noaia COP). Oe? noaie oeeoinoaoe/ii? oa?ai?? ?iaeoeothoue aeoeaaoe?th A-ee?oei ? iiyao aai ca?eueoaiiy ??aiy aeni?an?? ?yaeo aeoeaaoe?eieo aioeaai?a, na?aae yeeo CD25R (?aoeaioi? IL-2) oa CD95 (Fas-?aoeaioi?). 5. A i?ioean? e?eoaaiiy i?aaei?cieiiii, a oaeiae oei?aiaooeeeii c i?aaei?cieiiii o 54% oa 75% oai?eo ia o?ii?/io e?ioi?aeio eaeeai?th niinoa??aa?oueny ei?ioeio?eaaea ?ai?n?y ?ioiiiai oneeaaeiaiiy, ui noi?iaiaeaeo?oueny i?i?iaeueieie ci?iaie aeni?an?? A-ee?oeiieo aioeaai?a. I?aaei?cieii aeeeeea? iii??i? iciaee aeoeaaoe?? A-ee?oei (ca?eueoaiiy aeni?an?? CD25R ? CD11b). I?ae ae??th oei?aiaooeeeo ia A-e?ioioeeoao cieaeo?oueny aeni?an?y aioeaaia i?ie?oa?oth/eo ee?oei, ui ?aaao? c IEAO ?II-38. 6. Ei?ioei/ania iiaia ?ai?n?y ?ioiiiai i?ioeano i?ae ae??th i?aia?ao?a oeiona c i?aaei?cieiiii aeieea? o 50% oai?eo ia o?ii?/io e?ioi?aeio eaeeai?th, ui i?eaiaeeoue aei ciaioaiiy ??aiy aeni?an?? iiiaeeiieeo A-ee?oeiieo ia?ea??a oa aei i?i?iaeueieo iciae aeoeaaoe?? A-ee?oei. O i?ioean? e?eoaaiiy aeoeaaoi?aie O-nenoaie ?ioi?oaoo aaaiii c?inoa? e?euee?noue CD4+-ee?oei oa ii?iae?co?oueny ni?aa?aeiioaiiy Th/Ts. Naaine eaeeaieaciaoa?aco aeeeeeathoue a a?eueoino? aeiaaee?a (86 % iaoe??io?a) /anoeiao ee?i?/io ?ai?n?th aac ci?i aeni?an?? A-ee?oeiieo ia?ea??a oa c i?aeaeuaiiyi e?eueeino? CD25R+-ee?oei. 7. C?inoaiiy aeni?an?? Fas-?aoeaioi?a (CD95) ia eaeeai?/ieo ee?oeiao oai?eo ia o?ii?/io e?ioi?aeio eaeeai?th c ?ioiiei oneeaaeiaiiyi niinoa??aa?oueny o?eueee i?ney i?ia?ai oa?ai??, ui a?aecia/athoueny cia/iith aoaeoeai?noth. I?ae na?aaeiueith o?eaae?noth ?ai?n?? oa i?e?inoii ??aiy CD95+-ee?oei i?ney eo?no e?eoaaiiy ?nio? o?niee ei?aeyoe?eiee ca'ycie. 8. Ci?ie ai?noo O-ee?oei oa ?o ?ioii?aaoeyoi?ieo noaiiioeyoe?e o oai?eo ia A-ee?oeiio o?ii?/io e?ioi?aeio eaeeai?th c ?ioiieie oneeaaeiaiiyie i?e canoinoaaii? ??cieo noai e?eoaaiiy iaiaeiicia/i? ? i?iyaeythoueny a ca?eueoaii? aeni?an?? oiai /e ?ioiai O-ee?oeiiiai ia?ea?a, a oaeiae o i?aeaeuaii? ni?aa?aeiioaiiy CD4+/CD8+, iacaeaaeii a?ae aoaeoeaiino? oa?ai??. I?AEOE*I? ?AEIIAIAeAOe?? — I?e e?eoaaii? ?ioiieo oneeaaeiaiue o?ii?/ii? e?ioi?aeii? eaeeai??, ui i?io?ea? aac a?ia?ieac?? i?aai?a e?ioi?aeii? nenoaie, ii?yae c aaceniith oa?ai??th ei?oeeinoa?i?aeieie ai?iiiaie aeioe?eueii aeeth/aoe a?ie?enoei ye i?aia?ao, ui ca?eueoo? aeni?an?th Fas-aioeaaia. — O oai?eo ia A-ee?oeiio o?ii?/io e?ioi?aeio eaeeai?th, ui i?io?ea? c ae?aaeaiith a?ia?ieac??th i?aai?a e?ioi?aeii? nenoaie, i?e aeieeiaii? ?ioiieo oneeaaeiaiue iaea?eueo ?aoe?iiaeueii i?iaiaeeoe e?eoaaiiy ca noaiith NI?. — I?e ?aoeeaeeaoth/eo ?ioiieo oneeaaeiaiiyo o?ii?/ii? e?ioi?aeii? eaeeai?? oa iaaiaeaee?inueeeo e?ioii iecueeiai nooiaiy ceiye?niino?, iniaeeai o oai?eo c ae?aaeaiith nieaiiiaaae??th, ?aeiiaiaeo?oueny nieaiaeoii?y ye iaea?eueo aoaeoeaiee iaoiae e?eoaaiiy ?ioiieo oneeaaeiaiue o?ii?/ieo e?ioii?ie?oa?aoeaieo caoai?thaaiue. — Eaeeaieaciaoa?ac aeioe?eueii canoiniaoaaoe i?e aeieeiaii? ?ioiiiai oneeaaeiaiiy o oai?eo c a?ia?eaeeioeeoicii a o?aaioieo aeiaaeeao ye aoai i?aeaioiaee aei ?ioeo iaoiae?a (nieaiaeoii??), a oaeiae o oai?eo ia o?ii?/io e?ioi?aeio eaeeai?th, ?acenoaioieo aei o?i?ioa?ai??, oa i?e iayaiino? i?ioeiieac?a aei nieaiaeoii??. NIENIE IIOAE?EIAAIEO I?AOeUe 1. Loginsky V.E., Vygovska Ya.I., Tsiapka O.M., Matlan V.L., Karol Yu.S. Immunophenotypic characterization of blood lymphoid cells in chronic lymphocytic leukemia complicated by immune cytopenias// Yeni. iieieiaey.- 1996.- 18, ?1.- N.37-42. 2. Auaianeay ss.E., Eiaeineee A.A., Oeyiea I.I., Iaoeai A.E., Ea?ieue TH.N. Aniaeou noaaee?iaaiey o?iie/aneiai eeioieaeeica n o/?oii oaiioeie/aneie oa?aeoa?enoeee eaeeiciuo eeaoie// I?iaeaiu aaiaoieiaee.- 1996.- ?1.-N.18-23. 3. Ea?ieue TH.N. E?eoaaiiy a?ie?enoeiii aooi?ioiieo oneeaaeiaiue o oai?eo ia o?ii?/io e?ioi?aeio eaeeai?th// Acta med. Leopol.- 1996.- II, ?3-4.- N.57-59. 4. Aeaianueea ss.?., Oeyiea I.I., Ea?ieue TH.N. Aniaeoe e?eoaaeueii? oaeoeee o ?ac? o?ii?/ieo e?ioii?ie?oa?aoeaieo caoai?thaaiue, oneeaaeiaieo ?ioiieie oeeoiiai?yie// Oe?. iaaee/iee /aniien.- 1998.- 3(5).- N.39-42. 5. Iaoeai A.E., Oeyiea I.I., Ea?ieue TH.N. E?eoaaiiy oai?eo ?c ceiye?nieie e?ioii?ie?oa?aoeaieie caoai?thaaiiyie oa aooi?ioiieie oneeaaeiaiiyie// Iaoa??aee Y eiia?ano na?oiai? oaaea?aoe?? Oe?a?inueeeo e?ea?nueeeo oiaa?enoa.- Aei?i?iiao?ianuee.- 1994.- N.110. 6. Iaoeai A.E., Aoiai ?.E., Ea?ieue TH.N., Oaa/aiei E.A., Ei?ieue/oe I.N. ?ioiiiiaeoethth/a oa?ai?y aooi?ioiieo oneeaaeiaiue o?ii?/ii? e?ioi?aeii? eaeeai?? (OEE)// Oace aeii. III Oe?. c'?caeo aaiaoieia?a ? o?ainooc?ieia?a (Noie).- E.:1995.- N.49. 7. Vygovska Y., Loginsky V., Tsiapka O., Karol Y., Matlan V. Immu-nophenotypic characterization of blood lymphoid cells in chronic lymphocytic leukemia complicated by immune cytopenias// Abstr. Book XIII Meeting Intern. Soc. of Haematology (European & African Division).- Istanbul (Turkiye).- 1995.- ?849. 8. Vygovska Y.I., Loginsky V.O., Tsiapka O.M., Matlan V.L., Karol Y.S., Eustakhevych Y.L. Autoimmune thrombocytopenic purpura in chronic B-cell leukemia// Ann. Hematology.- 1996.- 72, Suppl.1.- ?96. 9. Vygovska Y., Matlan V., Tsiapka O., Karol Y., Loginsky V., Lebid' G. Immunophenotype of leukemic cells on different stages of chronic lymphocytic leukemia (CLL)// Abstr. Book XIV Meeting of the Intern. Soc. of Haematology.- Stockholm (Sweden).- 1997.- P.112. 10. Wyhowska J., Logynskyj V., Ciapka O., Karol Y., Matlan W. Immunologiczny fenotyp komorek limfoidalnych krwi obwodowej u chorych na przewlek?? bia?aczke limfatyczn?, powik?an? autoimmunnymi cytopeniami, w trakcie leczenia// Acta Haematol. Pol.- 1997.- 28, Suppl.3.- P.243. 11. Ea?ieue TH.N. Oa?aeoa?enoeea ?ioiioaiioeio e?ioi?aeieo ee?oei oai?eo ia o?ii?/io e?ioi?aeio eaeeai?th (OEE), oneeaaeiaio aooi?ioiieie aaiioeeoiiai?yie, a i?ioean? o?i?ioa?ai?? ca noaiith NI?// Oace aeii. iaoeiai-i?aeoe/ii? eiioa?aioe?? iieiaeeo a/aieo oa oao?aoe?a "No/ani? i?iaeaie aaiaoieia?? oa o?ainooc?ieia??".- Ee?a.- 1998.- N.17. 12. Matlan V., Karol Y., Tsiapka O., Lebid G., Prytulka A., Vygovska Y., Novak V. and Loginsky V. Effect of treatment on T-cell disturbances in chronic lymphocytic leukemia with autoimmune complications// Acta Med. Austr.- 1998.- 25, Suppl 46.- P.29. 13. Vygovska Y., Loginsky V., Tsiapka O., Karol Y., Matlan V. Immunophenotypic changes and clinical efficacy of chemotherapy in chronic lymphocytic leukemia with immune cytopenias// Acta Haematol. Pol.- 1998.- 29, Suppl.1.- P.118. AIIOAOe?ss Ea?ieue TH.N. Aieea e?eoaaiiy ia oaiioei?/io oa?aeoa?enoeeo e?ioi?aeieo ee?oei oai?eo ia o?ii?/i? e?ioii?ie?oa?aoeai? caoai?thaaiiy c ?ioiieie oeeoiiai?yie.- ?oeiien. Aeena?oaoe?y ia caeiaoooy iaoeiaiai nooiaiy eaiaeeaeaoa iaaee/ieo iaoe ca niaoe?aeuei?noth 14.01.31 — aaiaoieia?y oa o?ainooc?ieia?y.- Ee?anueeee iaoeiai-aeine?aeiee ?inoeooo aaiaoieia?? oa ia?aeeaaiiy e?ia?, Ee?a, 1998. A aeena?oaoe?? i?iaaaeaii aeine?aeaeaiiy ?ioiieia?/iiai oaiioeio e?ioi?aeieo ee?oei ia?eoa?e/ii? e?ia? oai?eo ia o?ii?/i? e?ioii?ie?oa?aoeai? caoai?thaaiiy (OEIC) c ?ioiieie oeeoiiai?yie a i?ioean? ??cieo iaoiae?a e?eoaaiiy. Aeyaeai? ci?ie ?ioiieia?/iiai oaiioeio e?ioioeeo?a ia?eoa?e/ii? e?ia? oai?eo ia o?ii?/io e?ioi?aeio eaeeai?th (OEE) c ?ioiieie oneeaaeiaiiyie iaiaeiaeia? a i?ioean? ??cieo iaoiae?a e?eoaaiiy. I?ae aoaeoeai?noth ie?aieo iaoiae?a e?eoaaiiy ?ioiieo oneeaaeiaiue OEIC oa ci?iaie ?ioiioaiioeio e?ioioeeo?a ia?eoa?e/ii? e?ia? ?nio? iaaia caeaaei?noue. Iaea?eueo cia/i? ci?ie a aeni?an?? A-ee?oeiieo aioeaai?a, nooo?aa c?inoaiiy aeni?an?? iieaeoee aiiioico CD95 ? iaeo?eaae?oa ?ai?n?y ?ioiiiai i?ioeano niinoa??aathoueny i?ney nieaiaeoii??, i?iaaaeaiiy eo?no NI? oa i?ney e?eoaaiiy a?ie?enoeiii c i?aaei?cieiiii. Aeyaeai? a?aei?iiino? ?ioiioaiioeio e?ioioeeo?a o i?ioean? e?eoaaiiy oai?eo OEIC c ?ioiieie oneeaaeiaiiyie iiaeooue neoaoaaoe iniiaith aeey ?icoi?iiy iaoai?cio ae?? ie?aieo e?eoaaeueieo caoiae?a oa iaa?oiooaaiiy aeai?o oa?ai??. Eeth/ia? neiaa: o?ii?/i? e?ioii?ie?oa?aoeai? caoai?thaaiiy, ?ioii? oneeaaeiaiiy, ?ioiioaiioei, e?eoaaiiy. AIIIOAOeEss Ea?ieue TH.N. Aeeyiea ea/aiey ia oaiioeie/aneoth oa?aeoa?enoeeo eeioieaeiuo eeaoie aieueiuo o?iie/aneeie eeioii?ieeoa?aoeaiuie caaieaaaieyie n eiioiiuie oeeoiiaieyie.- ?oeiienue. Aeenna?oaoeey ia nieneaiea o/aiie noaiaie eaiaeeaeaoa iaaeeoeeineeo iaoe ii niaoeeaeueiinoe 14.01.31 — aaiaoieiaey e o?ainooceieiaey.- Eeaaneee iao/ii-enneaaeiaaoaeueneee einoeooo aaiaoieiaee e ia?aeeaaiey e?iae, Eeaa, 1998. A aeenna?oaoeee i?iaaaeaii enneaaeiaaiea eiioiieiae/aneiai oaiioeia eeioieaeiuo eeaoie ia?eoa?e/aneie e?iae aieueiuo o?iie/aneeie eeioii?ieeoa?aoeaiuie caaieaaaieyie (OEIC) n eiioiiuie oeeoiiaieyie a i?ioeanna ?aciuo iaoiaeia ea/aiey. Iaia?oaeaiiua eciaiaiey eiioiieiae/aneiai oaiioeia eeioioeeoia ia?eoa?e/aneie e?iae aieueiuo o?iie/aneei eeioieaeiui eaeeicii (OEE) n eiioiiuie ineiaeiaieyie iaiaeeiaeiau a i?ioeanna ?aciuo iaoiaeia ea/aiey. Iaaeaeo yooaeoeaiinoueth ioaeaeueiuo iaoiaeia ea/aiey eiioiiuo ineiaeiaiee OEIC e eciaiaieyie eiioiioaiioeia eeioioeeoia ia?eoa?e/aneie e?iae nouanoaoao ii?aaeaeaiiay caaeneiinoue. Naiua cia/eoaeueiua eciaiaiey a yeni?annee A-eeaoi/iuo aioeaaiia, nouanoaaiiia aic?anoaiea yeni?annee iieaeoeu aiiioica CD95 e naiay i?iaeieaeeoaeueiay ?aienney eiioiiiai i?ioeanna iaaethaeaaony iinea nieaiyeoiiee, i?iaaaeaiey eo?na NI? e ea/aiey aeie?enoeiii e i?aaeiecieiiii. Iaia?oaeaiiua ?acee/ey eiioiioaiioeia eeioioeeoia a i?ioeanna ea/aiey aieueiuo OEIC n eiioiiuie ineiaeiaieyie iiaoo neoaeeoue iniiaie aeey iiieiaiey iaoaiecia aeaenoaey ioaeaeueiuo ea/aaiuo ia?ii?eyoee e iainiiaaiey auai?a oa?aiee. Eeth/aaua neiaa: o?iie/aneea eeioii?ieeoa?aoeaiua caaieaaaiey, eiioiiua ineiaeiaiey, eiioiioaiioei, ea/aiea. ANNOTATION Karol Yu.S. Treatment impact on phenotypic characterization of lymphoid cells in patients with chronic lymphoproliferative disorders with immune cytopenias.- Manuscript. Thesis for a candidate's degree of medical sciences by speciality 14.01.31 — Hematology and transfusiology.- Research Institute of Hematology and Blood Transfusion, Kyiv, 1998. The dissertation is devoted to the immunophenotype studies of peripheral blood lymphoid cells in patients with chronic lymphoproliferative disorders (CLPD), complicated by immune cytopenias undergoing different treatment regimen. Revealed changes of blood lymphocytes immunologic phenotype in chronic lymphocytic leukemia (CLL) patients with immune complications are variable during different treatment schemes. There are some correlations between results of the therapy for immune complications and immunophenotypic changes of peripheral blood lymphocytes. The most significant changes of B-cell markers expression, considerable augmentation of apoptotic molecule CD95 expression, and the most durable remission in immune process were observed after splenectomy, after the COP-regimen and after the treatment by vincristine and prednisolon. Revealed differences of lymphocyte immunophenotype in the treated groups of CLPD patients with immune complications may be basic for action mechanism's interpretation of some therapy methods and validity for the treatment choice. Key words: chronic lymphoproliferative disorders, immune complications, immunologic phenotype, treatment.

Похожие записи